Centronuclear myopathy

Centronuclear myopathy
Synonyms	CNM
Pronounce
Field	Neurology, Genetics, Musculoskeletal
Symptoms	Muscle weakness, hypotonia, delayed motor milestones, respiratory difficulties, and in severe cases, cardiac complications
Complications	Respiratory failure, scoliosis, joint contractures, cardiac arrhythmias, and difficulty with swallowing
Onset	Typically presents in infancy or early childhood, though some forms can appear later
Duration	Lifelong, with severity varying greatly depending on the subtype
Types	X-linked (most common), autosomal dominant, autosomal recessive
Causes	Genetic mutations, most commonly in the MTM1 gene (X-linked form) or in genes such as DNM2, AMP1, RYR1 for autosomal forms
Risks	Family history of centronuclear myopathy, genetic predisposition, male sex (in X-linked form)
Diagnosis	Clinical presentation, genetic testing (for MTM1, DNM2, AMP1, RYR1 mutations), muscle biopsy showing central nuclei in muscle fibers
Differential diagnosis	Duchenne muscular dystrophy, Myotonic dystrophy, Becker muscular dystrophy, Congenital muscular dystrophy, other forms of muscular dystrophy
Prevention	No primary prevention; genetic counseling may be beneficial for families with a history of the disease
Treatment	Symptomatic management, physical therapy to maintain muscle strength and function, respiratory support, and orthopedic interventions for scoliosis or joint contractures
Medication	No specific drug therapy; medications for managing symptoms such as respiratory support and anticonvulsants if needed for seizures
Prognosis	Variable; in severe cases (particularly X-linked form), life expectancy may be reduced due to respiratory failure, while milder forms may allow for normal or near-normal life expectancy
Frequency	Rare, with an estimated prevalence of 1 in 50,000 to 1 in 100,000 individuals
Deaths	Higher mortality rate in severe cases due to respiratory failure or cardiac complications

A group of rare congenital myopathies

Centronuclear myopathy (CNM) is a group of rare congenital myopathies characterized by muscle weakness and distinctive histological features, notably the presence of centrally located nuclei in muscle fibers. These myopathies are genetically heterogeneous and can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner.

Classification

Centronuclear myopathy is classified based on the mode of inheritance and the specific genetic mutations involved. The main types include:

• X-linked centronuclear myopathy: Caused by mutations in the MTM1 gene, this form is also known as myotubular myopathy. It primarily affects males and is the most severe form, often presenting in infancy.

• Autosomal dominant centronuclear myopathy: Often associated with mutations in the DNM2 gene, this form can present at any age and varies in severity.

• Autosomal recessive centronuclear myopathy: This form can be caused by mutations in several genes, including BIN1, RYR1, and TTN. It typically presents in childhood or adolescence.

Pathophysiology

The hallmark of centronuclear myopathy is the abnormal positioning of nuclei in the center of muscle fibers, rather than at the periphery. This is thought to result from defects in muscle cell development and maintenance. The specific pathophysiological mechanisms vary depending on the genetic mutation involved. For example, mutations in the MTM1 gene affect the protein myotubularin, which is involved in phosphoinositide metabolism, while DNM2 mutations affect dynamin 2, a protein involved in endocytosis and membrane trafficking.

Clinical Features

The clinical presentation of centronuclear myopathy can vary widely depending on the type and severity of the condition. Common features include:

• Muscle weakness, particularly in the proximal muscles
• Hypotonia (reduced muscle tone)
• Delayed motor milestones
• Respiratory difficulties, especially in severe cases
• Facial muscle weakness, leading to a characteristic facial appearance

Diagnosis

Diagnosis of centronuclear myopathy typically involves a combination of clinical evaluation, muscle biopsy, and genetic testing. Muscle biopsy reveals the characteristic central nuclei in muscle fibers. Genetic testing can identify specific mutations responsible for the condition.

Management

There is currently no cure for centronuclear myopathy, and management focuses on supportive care to improve quality of life. This may include:

• Physical therapy to maintain muscle strength and flexibility
• Respiratory support, such as non-invasive ventilation
• Orthopedic interventions to address skeletal deformities
• Nutritional support to ensure adequate caloric intake

Prognosis

The prognosis for individuals with centronuclear myopathy varies widely depending on the type and severity of the condition. X-linked myotubular myopathy often has a poor prognosis due to severe respiratory involvement, while other forms may have a more favorable outcome with appropriate management.

Related pages

• Congenital myopathy
• Muscle biopsy
• Genetic testing
• Respiratory support

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia